Dova Health Intelligence selected for exclusive Canadian AI Life Sciences Delegation to South Korea

‍

We’re proud to announce that Dova Health Intelligence has been selected as one of a small cohort of Canadian companies to participate in the Canadian AI in Life Sciences Innovation R&D Partnering Delegation to South Korea, taking place September 23–25, 2025, in Seoul.

‍

Organized by the Embassy of Canada in Seoul in collaboration with the National Research Council Industrial Research Assistance Program (NRC IRAP) under the Canadian International Innovation Program (CIIP), this highly selective delegation brings together a handful of Canadian innovators applying artificial intelligence to life sciences. The goal is to build high-impact R&D collaborations and unlock strategic opportunities with leading South Korean pharmaceutical firms, biotech companies, and research institutions.

‍

Over three days, participants will engage in market briefings, site visits to top Korean pharma and AI centers, tailored one-on-one matchmaking meetings, and high-visibility programming at AI Pharma Korea 2025, the country’s premier conference on AI-driven drug discovery and digital health. Dova is honoured to be featured in the dedicated Canada session at the event, showcasing cutting-edge Canadian innovation to a global audience.

‍

South Korea is one of the world’s fastest-growing life sciences markets, with strong public investment and a rapidly evolving AI healthcare ecosystem. Participation in this delegation represents a unique opportunity to deepen international partnerships, explore new research directions, and accelerate the global impact of our AI technologies for IBD diagnosis and care.

‍

We look forward to representing Canadian health tech innovation abroad and connecting with future collaborators in Seoul this fall.

If you’ll be attending, we’d love to connect.

‍